Abstract
BackgroundWhile vaccinia virus (VACV) has demonstrated robust oncolytic activity, we sought to enhance therapeutic efficacy by engineering VACV to express interleukin-12 (IL-12), a potent NK and T cell activating cytokine...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
